Literature DB >> 34405228

Aducanumab and the certainty of evidence.

Jenny McCleery1, Terence J Quinn1,2.   

Abstract

Entities:  

Keywords:  Cochrane; aducanumab; dementia; evidence; older people

Mesh：

Substances：

Year:  2021        PMID： 34405228      PMCID： PMC8581393          DOI： 10.1093/ageing/afab167

Source DB:  PubMed          Journal:  Age Ageing        ISSN： 0002-0729            Impact factor:   12.782


× No keyword cloud information.
  5 in total

1.  Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.

Authors:  James A R Nicoll; George R Buckland; Charlotte H Harrison; Anton Page; Scott Harris; Seth Love; James W Neal; Clive Holmes; Delphine Boche
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

2.  Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.

Authors:  David S Knopman; David T Jones; Michael D Greicius
Journal:  Alzheimers Dement       Date:  2020-11-01       Impact factor: 21.566

Review 3.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

Authors:  Kevin Mullane; Michael Williams
Journal:  Biochem Pharmacol       Date:  2012-11-23       Impact factor: 5.858

Review 4.  Using quality assessment tools to critically appraise ageing research: a guide for clinicians.

Authors:  Jennifer Kirsty Harrison; James Reid; Terry J Quinn; Susan Deborah Shenkin
Journal:  Age Ageing       Date:  2017-05-01       Impact factor: 10.668

5.  Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.

Authors:  Edo Richard; Melina G H E den Brok; Willem A van Gool
Journal:  Alzheimers Dement       Date:  2021-05-31       Impact factor: 21.566
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.